<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02809144</url>
  </required_header>
  <id_info>
    <org_study_id>0472</org_study_id>
    <nct_id>NCT02809144</nct_id>
  </id_info>
  <brief_title>A Novel Combination of Peripheral Nerve Blocks for Patients Scheduled for Shoulder Surgery</brief_title>
  <official_title>A Novel Combination of Peripheral Nerve Blocks for Patients Scheduled for Shoulder Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital of North Norway</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital of North Norway</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Interscalene block has been the traditional regional anesthesia for shoulder surgery and
      postoperative pain. However, the risk of phrenic nerve palsy and irreversible nerve injury
      have encouraged search for alternative methods.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Analyzing block effects of the lateral sagittal infraclavicular brachial plexus
      block(posterior and lateral chord), the investigators found it affecting all shoulder
      relevant nerves , except for the suprascapular and the supraclavicular nerves.

      Accordingly, by combining a superficial cervical plexus block, suprascapular nerve block and
      block of the posterior and lateral chords infraclavicularly, the investigators believe this
      novel combination would provide anesthesia for patients scheduled for shoulder surgery.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Actual">November 2016</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The need for general anaesthesia</measure>
    <time_frame>Intraoperatively</time_frame>
    <description>Investigators will record the number of patients who need to be converted to general anaesthesia</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Surgeons satisfaction with the working conditions</measure>
    <time_frame>Intraoperatively</time_frame>
    <description>Graded in a) Good and b) Poor</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Nerve block</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>One novel nerve block combination</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Nerve block</intervention_name>
    <description>Nerve block: 31 ml ropivacaine 7.5 mg/ml (Lateral sagittal infraclavicular brachial plexus block) + 4 ml ropivacaine 5 mg/ml (suprascapular nerve block) + 5 ml ropivacaine 5 mg/ml (superficial cervical plexus block)</description>
    <arm_group_label>Nerve block</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients scheduled for shoulder surgery.

          -  American Society of Anesthesiologist grad I-III,

          -  18-70 years,

          -  BMI 20-35,

        Exclusion Criteria:

          -  Pregnancy,

          -  coagulopathy,

          -  allergy to local anesthetics,

          -  atrioventricular block,

          -  peripheral neuropathy or drug-treated diabetes.

          -  Patients using anticoagulation other than acetylsalicylic acid or dipyridamol will be
             excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lars Marius Ytrebø, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of North Norway</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital of North Norway</name>
      <address>
        <city>Tromsø</city>
        <state>Troms</state>
        <zip>9038</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 25, 2015</study_first_submitted>
  <study_first_submitted_qc>June 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 22, 2016</study_first_posted>
  <last_update_submitted>December 5, 2016</last_update_submitted>
  <last_update_submitted_qc>December 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital of North Norway</investigator_affiliation>
    <investigator_full_name>Lars Marius Ytrebo</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

